Beyond the Pill: How Logistics Powers Biotech's Multi-Disease Future

SPRING BRANCH, TX – March 27, 2026 – In a move that highlights a critical shift in the pharmaceutical landscape, integrative logistics firm Callan JMB Inc. today announced its central role in scaling up a promising multi-indication therapeutic platform. The company will provide independent infrastructure and oversight for Biostax Corp’s JKB-122 (Lodonal™), an immune restoration therapy, as it advances toward late-stage clinical trials. This collaboration, which includes formulation specialists DifGen Pharmaceuticals and Aveva Drug Delivery Systems, signals a future where the delivery and deployment of a drug are just as innovative as its chemical composition.

The partnership aims to establish a robust, U.S.-based manufacturing and supply chain framework for JKB-122, a therapy with the potential to treat a wide array of chronic conditions. Callan JMB’s involvement ensures the entire process—from manufacturing to distribution—is built to meet the stringent standards of federal agencies like the Biomedical Advanced Research and Development Authority (BARDA), the Department of Defense (DoD), and the Department of Veterans Affairs (VA).

A New Blueprint for Therapeutic Development

This initiative represents more than just a single drug's progression; it is a case study in the burgeoning field of platform-based therapeutic development. Instead of creating a new drug for each disease, this model leverages a single, versatile molecule across multiple indications. JKB-122, a long-acting Toll-like Receptor 4 (TLR4) antagonist, is designed to restore the body’s immune homeostasis, targeting the upstream cause of inflammation rather than downstream symptoms. This mechanism gives it potential applications in conditions as varied as Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), more commonly known as Long COVID, as well as autoimmune hepatitis, metabolic liver diseases, and even chronic pain.

"This marks an important step in advancing our program into a platform model," said Noreen Griffin, Chief Executive Officer of Biostax Corp, which operates as Attune Biotech. "Establishing U.S.-based manufacturing and a unified CMC framework creates the foundation for multi-indication development and future commercialization. Callan JMB was selected for its ability to provide independent oversight across manufacturing and supply chain systems—helping ensure the level of rigor, compliance, and readiness required for federal programs and large-scale deployment."

Attune Biotech is advancing JKB-122 using the FDA's 505(b)(2) regulatory pathway, a streamlined process that allows the company to leverage existing safety data. With over 150,000 patient-years of safety data already accumulated across parallel clinical programs, this approach significantly de-risks development and accelerates the timeline to potential approval.

The 'Swiss Army Knife' Therapeutic

The promise of JKB-122 lies in its remarkable breadth. The lead program for Long COVID has already received FDA authorization to proceed with a Phase 2b/3 clinical study designed to evaluate immune restoration and functional recovery. This is a critical area of unmet need following the global pandemic.

Beyond Long COVID, the platform shows significant potential in other complex diseases:
* Liver Disease: JKB-122 has received Orphan Disease Designation from the FDA for Autoimmune Hepatitis (AIH), and a Phase 2 trial has been initiated in the U.S. Programs for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Steatohepatitis (MASH) are also underway.
* HIV: Studies are planned for HIV immune non-responders, a population that struggles to recover immune function despite viral suppression. Research has shown the therapy can reduce chronic inflammation and increase CD4+ counts.
* Veteran Health: The platform's potential impact on military and veteran populations is particularly compelling. Clinical trials in DoD and VA populations have already demonstrated a 58% reduction in chronic pain, a 62% improvement in PTSD symptoms, and a significant increase in deployment readiness and overall quality of life.

This multi-front approach transforms the drug from a single-shot solution into a versatile therapeutic tool, capable of addressing some of the most challenging chronic conditions facing modern medicine.

The Unseen Engine: Why Logistics and Oversight are Critical

While the science behind JKB-122 is groundbreaking, its journey to patients depends on an equally sophisticated, yet often overlooked, operational backbone. This is where Callan JMB's role becomes indispensable. The company is not merely a shipping contractor but an integrated oversight partner ensuring the integrity of the entire supply chain.

"Callan JMB has deep experience supporting complex, regulated programs where execution, compliance, and visibility are critical," stated Wayne Williams, President and Chief Executive Officer of Callan JMB. "Our role is to provide independent infrastructure and oversight across manufacturing, storage, monitoring, packaging, and distribution—helping ensure these programs are built to scale and ready for real-world clinical, commercial, and government deployment."

This oversight is crucial for federal readiness. Callan JMB brings over two decades of experience managing assets for the Strategic National Stockpile (SNS) and other government bodies. Their expertise in cGMP-compliant warehousing, cold chain logistics, and emergency preparedness means the JKB-122 platform is being built from the ground up for potential rapid, large-scale deployment in a national health crisis. A surge-readiness simulation in late 2024 successfully demonstrated the company could deliver 500,000 units anywhere in the continental U.S. within 48 hours, meeting stringent federal benchmarks.

Building the Platform: Manufacturing and Collaboration

Bringing a platform therapeutic to life requires specialized manufacturing capabilities. The collaboration has enlisted DifGen Pharmaceuticals and its subsidiary, Aveva Drug Delivery Systems, to lead the U.S.-based technology transfer and GMP manufacturing scale-up. Their expertise in formulation development is essential for creating the various dose strengths, titration regimens, and sustained-release versions needed to support a multi-indication platform.

"We are very excited to be part of this collaboration and to support the advancement of what we believe is a highly innovative upstream immune restoration platform," said Ramandeep Singh Jaj and Santhanakrishnan Srinivasan, Founders and Co-CEOs of DifGen Pharmaceuticals. "This program is unique in that it is built around a platform formulation and manufacturing strategy across multiple dose strengths and multiple indications. As the platform expands into additional indications, we look forward to supporting not only manufacturing and formulation development, but also a broader role in supporting future clinical development programs built on this platform."

This integrated approach—combining innovative science, flexible manufacturing, and compliant logistics—reflects a broader industry momentum. As medicine becomes more personalized and complex, the success of a therapeutic will increasingly depend on the strength of the ecosystem built around it. This collaboration provides a clear blueprint for how to construct that ecosystem, ensuring that a drug's potential in the lab can be fully realized for patients in the real world.